+

WO2002066492A3 - Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. - Google Patents

Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. Download PDF

Info

Publication number
WO2002066492A3
WO2002066492A3 PCT/FR2002/000638 FR0200638W WO02066492A3 WO 2002066492 A3 WO2002066492 A3 WO 2002066492A3 FR 0200638 W FR0200638 W FR 0200638W WO 02066492 A3 WO02066492 A3 WO 02066492A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific antibody
therapeutic uses
pharmaceutical composition
composition containing
containing same
Prior art date
Application number
PCT/FR2002/000638
Other languages
English (en)
Other versions
WO2002066492A2 (fr
Inventor
Pierre Marie Martin
L Houcine Ouafik
Original Assignee
Sanofi Synthelabo
Assist Publ Hopitaux De Paris
Pierre Marie Martin
L Houcine Ouafik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Assist Publ Hopitaux De Paris, Pierre Marie Martin, L Houcine Ouafik filed Critical Sanofi Synthelabo
Priority to AU2002238673A priority Critical patent/AU2002238673A1/en
Publication of WO2002066492A2 publication Critical patent/WO2002066492A2/fr
Publication of WO2002066492A3 publication Critical patent/WO2002066492A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un anticorps spécifique de l'adrénomedulline, utile dans le traitement de cancers. L'invention se rapporte également à des compositions pharmaceutiques contenant un anticorps anti-adrénomedulline et à leurs applications thérapeutiques.
PCT/FR2002/000638 2001-02-20 2002-02-20 Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. WO2002066492A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002238673A AU2002238673A1 (en) 2001-02-20 2002-02-20 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/02291 2001-02-20
FR0102291A FR2821080B1 (fr) 2001-02-20 2001-02-20 Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques

Publications (2)

Publication Number Publication Date
WO2002066492A2 WO2002066492A2 (fr) 2002-08-29
WO2002066492A3 true WO2002066492A3 (fr) 2003-02-27

Family

ID=8860234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000638 WO2002066492A2 (fr) 2001-02-20 2002-02-20 Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.

Country Status (3)

Country Link
AU (1) AU2002238673A1 (fr)
FR (1) FR2821080B1 (fr)
WO (1) WO2002066492A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121375A1 (en) * 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
EP2589963A1 (fr) * 2011-11-04 2013-05-08 Université de Provence (Aix-Marseille 1) Diagnostic et traitement du cancer de la prostate indépendant des androgènes
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
MX2020010320A (es) 2018-04-02 2021-01-08 Amgen Inc Composiciones de erenumab y usos de las mismas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0622458A2 (fr) * 1993-04-26 1994-11-02 Shionogi & Co., Ltd. Adrénomédulline
WO1997007214A1 (fr) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Role fonctionnel de l'adrenomedulline (am) et du produit apparente a un gene (pamp) en pathologgie et physiologie chez l'homme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0622458A2 (fr) * 1993-04-26 1994-11-02 Shionogi & Co., Ltd. Adrénomédulline
WO1997007214A1 (fr) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Role fonctionnel de l'adrenomedulline (am) et du produit apparente a un gene (pamp) en pathologgie et physiologie chez l'homme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORGSTROM P ET AL: "COMPLETE INHIBITION OF ANGIOGENESIS AND GROWTH OF MICROTUMORS BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR NEUTRALIZING ANTIBODY: NOVEL CONCEPTS OF ANGIOSTATIC THERAPY FROM INTRAVITAL VIDEOMICROSCOPY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1 September 1996 (1996-09-01), pages 4032 - 4039, XP002918735, ISSN: 0008-5472 *
MILLER MAE JEAN ET AL: "Adrenomedullin expression in human tumor cell lines: Its potential role as an autocrine growth factor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 38, 1996, pages 23345 - 23351, XP002184272, ISSN: 0021-9258 *
ZHAO YUAN ET AL: "PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium.", ONCOGENE, vol. 16, no. 3, 22 January 1998 (1998-01-22), pages 409 - 415, XP001113057, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2002238673A1 (en) 2002-09-04
FR2821080A1 (fr) 2002-08-23
FR2821080B1 (fr) 2003-12-19
WO2002066492A2 (fr) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2004058837A3 (fr) Copolymere ampholytique et son utilisation
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2001070275A3 (fr) Conjugues de la camptothecine-acide polyglutamique et leurs procedes de preparation
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
DE69905170D1 (en) Thiazolopyrimidinderivate
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
TR200100054T2 (tr) Paroksetin metansülfonat
AU2386201A (en) Substituted sapogenins and their use
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
HUP0303469A3 (en) Phtalazinon-derivatives, their use and pharmaceutical compositions containing them
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
AU2003221096A1 (en) Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
GB0326221D0 (en) Therapeutic agents,compositions,preparations and uses
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载